3月27日 - ** 制药商Rigel Pharmaceuticals RIGL.O股价上涨3%至19.54美元
** RIGL称已与Annora Pharma就该公司的血液病药物Tavalisse专利诉讼 (link)，Tavalisse用于治疗对先前治疗无效的免疫性血小板减少症患者$(ITP)$。
** 诉讼始于 Annora 向 FDA 提交 Tavalisse 仿制药上市申请。
** ITP是一种免疫系统错误攻击和破坏血小板的疾病，导致血小板数量低和出血风险增加。
** 根据和解协议，Annora公司将获准从2032年第二季度开始销售其仿制药，或在某些情况下提前销售。
** Annora没有立即回应路透社的置评请求
** RIGL在过去12个月中上涨了33.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.